Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2022-10-31 Declaration of Voting R…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Number of shares and votes in Xspray Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a change in the number of shares and votes due to a directed share issue carried out in October 2022. This involves an increase in outstanding shares and share capital. This directly relates to changes in the company's capital structure or share count. Reviewing the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate category, as it covers announcements regarding new share issues or capital changes. Although it is a short announcement, the content is substantive regarding capital structure, making SHA more specific than the general RPA or RNS.
2022-10-31 English
Antal aktier och röster i Xspray Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short announcement from Xspray Pharma AB regarding a change in the total number of shares and votes following a directed share issue completed in October 2022. This directly relates to a change in the company's capital structure (increase in shares and share capital). This aligns best with the 'Capital/Financing Update' (CAP) definition, as it details the outcome of a financing activity (the share issue). Although it mentions the number of shares, it is not a general share issue announcement (SHA) but a specific notification about the result of a recent capital raise. Given the content focuses on the resulting capital change, CAP is the most appropriate fit over SHA, which usually covers the intent or mechanics of a new issue/split. The document is short and announces a specific corporate action result, not a comprehensive report.
2022-10-31 Swedish
Xspray Pharmas valberedning inför årsstämman 2023
Board/Management Information Classification · 99% confidence The document is titled "Xspray Pharmas valberedning inför årsstämman 2023" (Xspray Pharma's Nomination Committee ahead of the 2023 Annual General Meeting). It details the composition of the Nomination Committee and its mandate regarding proposals for the upcoming AGM (May 16, 2023), such as electing board members and auditors. This content directly relates to the preparatory work and structure surrounding the Annual General Meeting (AGM). While it is not the AGM presentation itself (AGM-R) or the proxy materials (PSI), the nomination committee composition is a key governance component often announced separately or as part of pre-AGM disclosures. Given the options, this announcement concerns the governance structure leading up to the AGM, specifically the nomination process. However, the core subject is the composition of the committee responsible for proposing board members and remuneration, which strongly aligns with Governance Information (CGR) or potentially the materials leading to the AGM (AGM-R/PSI). Since it is an announcement about the *composition* of the committee responsible for proposing board members and remuneration, it fits best under Governance Information (CGR) or potentially as a specific announcement related to the AGM process. Since the definitions are strict, and this is about the *composition* of the committee that handles board/remuneration proposals, CGR (Governance Information) is a strong fit, as is AGM-R (AGM Information) as it is explicitly about the AGM preparation. Given the focus on the 'valberedning' (Nomination Committee) which is a core governance body, CGR is appropriate. However, since the context is explicitly tied to the upcoming 'årsstämman' (AGM), and the committee's function is to prepare proposals *for* the AGM, AGM-R is also highly relevant. In many contexts, nomination committee announcements are grouped with AGM materials. I will classify it as AGM-R because the entire context is framed around the upcoming Annual General Meeting.
2022-10-25 Swedish
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023
Board/Management Information Classification · 99% confidence The document explicitly discusses the composition of the Nomination Committee for the upcoming Annual General Meeting (AGM) in 2023, including the names of the appointed members and the tasks they will undertake (proposals for board election, fees, etc.). It also provides a deadline for shareholders to submit proposals to the Nomination Committee before the AGM on May 16, 2023. This content is directly related to the preparatory work and information surrounding the AGM. While it is an announcement about a committee related to the AGM, the core subject matter is the committee's composition and function leading up to the meeting, which aligns best with 'AGM Information' (AGM-R) rather than just a general 'Report Publication Announcement' (RPA), as it contains substantive information about the AGM's governance structure setup. It is not a proxy statement (PSI) or a declaration of voting results (DVA).
2022-10-25 English
Xspray Pharma har genomfört en riktad emission som tillför bolaget 100 MSEK
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Xspray Pharma AB has successfully completed a fully subscribed directed new share issue (riktad nyemission) raising 100 MSEK. This action directly relates to the company's capital structure and fundraising activities. This fits the definition of 'Capital/Financing Update' (CAP). Although it is a press release, the core content is the financing event itself, not just an announcement that a report is attached (which would suggest RPA or RNS). The document details the terms, participants (institutional investors), use of proceeds, and resulting dilution, confirming it is a primary announcement about a capital event.
2022-10-17 Swedish
Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces that Xspray Pharma has successfully carried out a 'fully subscribed directed share issue' raising SEK 100 million. This action directly relates to fundraising, financing activities, and changes in the capital structure (increase in shares and share capital). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the AGM authorization, the core subject is the share issue itself, not the AGM materials or voting results. It is not a full 10-K, an earnings release, or a proxy statement. The document is a formal announcement of a capital raising event.
2022-10-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.